These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17909358)

  • 21. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
    Pai-Scherf LH; Carrasquillo JA; Paik C; Gansow O; Whatley M; Pearson D; Webber K; Hamilton M; Allegra C; Brechbiel M; Willingham MC; Pastan I
    Clin Cancer Res; 2000 May; 6(5):1720-30. PubMed ID: 10815890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
    Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM
    Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
    Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
    Herbertson RA; Tebbutt NC; Lee FT; MacFarlane DJ; Chappell B; Micallef N; Lee ST; Saunder T; Hopkins W; Smyth FE; Wyld DK; Bellen J; Sonnichsen DS; Brechbiel MW; Murone C; Scott AM
    Clin Cancer Res; 2009 Nov; 15(21):6709-15. PubMed ID: 19825951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody.
    Farrugia W; Scott AM; Ramsland PA
    PLoS One; 2009 Nov; 4(11):e7777. PubMed ID: 19901987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
    J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes.
    Waibel R; Mannhart M; O'Hara CJ; Brocklehurst C; Zangemeister-Wittke U; Schenker T; Lehmann HP; Weber E; Stahel RA
    Cancer Res; 1993 Jun; 53(12):2840-5. PubMed ID: 7684948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy.
    Testa L; Mano M; Arai RJ; Bonadio RC; Serrano SV; Zorzetto MMC; Crocamo S; Smaletz O; Freitas-Junior R; Hoff PM
    Clinics (Sao Paulo); 2021; 76():e3146. PubMed ID: 34644735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and therapeutic applications of monoclonal antibodies to small cell carcinoma of the lung.
    Okabe T; Takaku F
    Jpn J Clin Oncol; 1986 Sep; 16(3):243-52. PubMed ID: 3022033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G; Sharkey RM; Burton J; Zhang CH; Yeldell D; Matthies A; Alavi A; Losman MJ; Brenner A; Goldenberg DM
    Clin Colorectal Cancer; 2002 May; 2(1):31-42. PubMed ID: 12453334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
    Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
    J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
    Tong AW; Lee J; Stone MJ
    Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.
    Modak S; Guo HF; Humm JL; Smith-Jones PM; Larson SM; Cheung NK
    Cancer Biother Radiopharm; 2005 Oct; 20(5):534-46. PubMed ID: 16248769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
    Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.